Tablet Capping & Lamination: An OEM Defect Investigation Guide

Describe the defect without deciding the cause

Capping describes separation of a tablet portion resembling a cap; lamination describes separation into layers. When either is suspected, start with photographs and retained examples. Ask the technical reviewer to confirm the description. Several defects can look similar in a brief photograph, and the name alone does not identify the underlying mechanism.

Record the trial revision, sample location, timing, and any handling before the defect became visible. Note whether it appeared immediately, during a later operation, or after storage. Preserve acceptable tablets from the same trial where available. A useful investigation begins with a documented contrast rather than a claim that the material or press must be defective.

Request an evidence based hypothesis

Pharmaceutical compaction research has investigated mechanical responses related to capping. Another experimental study considered powder air release and lamination or capping tendencies. These findings concern selected drug blends. They help frame possible investigation questions, but they cannot establish the cause of a particular supplement tablet defect from appearance alone.

Ask the development team to list the plausible explanations supported by the available records and the next observation needed to distinguish them. Keep hypotheses separate from conclusions. This prevents the project from adding multiple formula or process changes before it has a clear understanding of what the proposed trial is intended to test.

Design a focused corrective trial

Review the identified ingredient grades, preparation route, tooling, and meaningful operating conditions. Agree on the trial comparison and the relevant finished tablet checks. Where several variables must change together, ask the reviewer to explain how that affects interpretation. The buyer should receive a practical account of the evidence rather than an unexplained new sample.

Plan observations beyond the first tablets made during the trial. Discuss the length and events needed to represent the suspected issue, without inventing a universal production duration. Include the later operations where the defect was originally seen. A correction deserves evaluation under conditions that can reveal whether the original concern remains.

Assess the whole product after a correction

A proposed adjustment may improve visible integrity while changing another characteristic. Compare the agreed dimensions, appearance, relevant physical results, and any performance checks used in the product specification. Keep the changed material list and sample revision explicit. The approval should describe the entire corrected tablet, not only the absence of one visible defect.

If the correction changes the preparation route, formula, or tooling, update the quotation and schedule assumptions. Review label implications where appropriate. Explain any further stability or finished-pack work needed before commercial approval. This lets the buyer separate a successful corrective trial from readiness to launch the revised product.

Close the investigation with a clear record

Summarize the initial defect, the supported explanation, the changes tested, and the evidence used to accept the result. Retain photographs and the relevant samples. Identify any remaining uncertainty and how it will be monitored. A record saying only that the press was adjusted will be difficult to use when a similar issue returns later.

Use the investigation to inform future component substitutions and repeat orders. Ask which conditions must remain controlled and what changes would trigger additional review. The goal is an understandable connection between the observed tablet behavior and the accepted development decision, with commercial specifications aligned to the configuration that actually passed the review.

Common questions